Prism Pharmaceuticals

Pharma

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 9 drugs with upcoming expirations

Activity

Key Events

Mar 2, 2026FDABosulif — BOSULIF

Jun 24, 2025FDAChantix — CHANTIX

Mar 31, 2025FDATygacil — TYGACIL

Dec 3, 2024FDABosulif — BOSULIF

Jul 16, 2024FDAInlyta — INLYTA

Sep 26, 2023FDABosulif — BOSULIF

Details

Company Info

Regulatory

Regulatory Timeline

20215 events

FDANov 22

Rapamune — FYARRO

Application NDA213312 (NDA)

FDANov 10

Pristiq — PRISTIQ

Application NDA021992

FDAOct 15

Chantix — TYRVAYA

Application NDA213978 (NDA)

FDAOct 15

Tyrvaya — TYRVAYA

Application NDA213978 (NDA)

FDASep 20

Pristiq — PRISTIQ

Application NDA021992

20222 events

FDASep 22

Inlyta — INLYTA

Application NDA202324

FDAMar 22

Rapamune — HYFTOR

Application NDA213478 (NDA)

20237 events

FDASep 26

Bosulif — BOSULIF

Application NDA217729 (NDA)

FDASep 26

Bosulif — BOSULIF

Application NDA217729 (NDA)

FDASep 26

Bosulif — BOSULIF

Application NDA203341

FDASep 26

Bosulif — BOSULIF

Application NDA217729

FDASep 7

Xalkori — XALKORI

Application NDA217581 (NDA)

FDAAug 18

Pristiq — PRISTIQ

Application NDA021992

FDAApr 20

Bosulif — BOSULIF

Application NDA203341

20242 events

FDADec 3

Bosulif — BOSULIF

Application NDA203341

FDAJul 16

Inlyta — INLYTA

Application NDA202324

20252 events

FDAJun 24

Chantix — CHANTIX

Application NDA021928

FDAMar 31

Tygacil — TYGACIL

Application NDA021821

20262 events

FDAMar 2

Bosulif — BOSULIF

Application NDA203341

FDAMar 2

Bosulif — BOSULIF

Application NDA217729

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)